Concurrent checkpoint blockade is critical in this phase, likely acting to sustain the proliferation and effector differentiation of pre-existing PD-1– CD8+ TILs, particularly the Tcf7+ memory-precursor-like subset, which is essential for an effective anti-tumor response and expands upon immunotherapy (29). Here, CD8A is linked to neoplasm.